Medicus Pharma’s Pipeline Targets Skin Cancer and Prostate Cancer

When most people think about cancer treatment, they picture chemotherapy, grueling surgeries, harsh drug regimens, and devastating side effects. Medicus Pharma (NASDAQ: MDCX) is working on clinical-stage assets that could change treatment for basal cell carcinoma and prostate cancer.

A Patch That Could Replace the Scalpel

Basal cell carcinoma is the most common form of cancer in the United States. For most patients, the standard response is surgical removal, and when the lesion is on the face or neck, it can mean visible scarring and significant recovery time.

SkinJect offers a different approach. The investigational therapy uses doxorubicin-containing dissolvable microneedle arrays to deliver a chemotherapeutic agent directly to the tumor site. This is done non-invasively, without surgery. In December 2025, Medicus completed enrollment of 90 patients in its randomized, double-blind, placebo-controlled Phase 2 study across nine clinical sites in the United States, and expects to report topline results soon.

BCC treatment represents approximately $2 billion in potential market opportunity. The company has also partnered with the Gorlin Syndrome Alliance to pursue an Expanded Access IND program, allowing patients with multiple, recurrent, or inoperable BCCs to access SkinJect under physician-supervised treatment protocols.

Gorlin Syndrome is a rare genetic disorder that causes patients to develop multiple basal cell carcinomas (sometimes dozens or hundreds of tumors over a lifetime ), making non-invasive treatments like SkinJect especially relevant for this population.

Treating Prostate Cancer Without Destroying the Heart

Another pillar of Medicus’s pipeline is Teverelix, a next-generation GnRH antagonist being developed through its subsidiary Antev. The drug targets advanced prostate cancer patients, a large and underserved population. An estimated 300,000 to 500,000 men in the United States are living with advanced prostate cancer.

The standard treatments for advanced prostate cancer come with a significant trade-off. Many standard hormone therapies can increase cardiovascular risk, an important concern because heart disease remains a leading cause of death among men with prostate cancer. Clinical data indicate that patients with pre-existing cardiovascular conditions may face a five- to six-fold higher incidence of major adverse cardiovascular events when treated with GnRH agonists compared with GnRH antagonists.

Teverelix is designed to address that gap directly. Unlike GnRH agonists, which can cause an initial surge in testosterone, Teverelix is designed to suppress hormone production without that flare effect, a mechanism that could be particularly important for patients with existing heart conditions.

In February 2026, Medicus received “study may proceed” clearance from the FDA to initiate a Phase 2b dose-optimization trial of Teverelix in men with advanced prostate cancer with elevated cardiovascular risk. The company estimates the combined addressable market for Teverelix at approximately $6 billion.

A Focused Bet on Precision Medicine

With SkinJect Phase 2 data expected imminently and the Teverelix trial now cleared to begin, Medicus is entering what could be a pivotal year. Both assets remain investigational — neither is approved for commercial use — but the pipeline is advancing, and the science behind each program is addressing real gaps in how we treat two conditions that affect millions of Americans.